Effect of vitamin D supplement in regulation of blood pressure

Investigating the effect of vitamin D3 supplementation in blood pressure control in essential hypertensive patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080901001165N57

Enrollment

200

Registered

2020-05-27

Start date

2014-10-23

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Intervention arm 1 : Pearl vitamin D 50000 Unit,PO, weekly, for 8 weeks (in addition to routine anti hypertensive drugs)

. Intervention 2: Control group: Pearl vitamin D 1000 U, PO, daily, for 8 weeks (in addition to routine anti hypertensive drugs).

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Essential Hypertension (Systolic pressure > 140 mmHg, Diastolic pressure > 90 mmHg) Adult patients from 18 to 65 y/o Patients under standard Anti-hypertensive agents Vitamin D level is less than 30.

Exclusion criteria

Exclusion criteria: Heart Failure (LVEF1.5mg/dl) Hepatic Failure Chronic Obstructive Pulmonary Disease (COPD): (FEV1/FVC <70%) Thyroid disorders Hyperparathyroidism Systemic infection Hypercalciurea

Design outcomes

Primary

Measure	Time frame
Systolic blood pressure. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: Sphygmomanometer, mmHg.;Diastolic blood pressure. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: Sphygmomanometer, mmHg.;Mean arterial pressure. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: Sphygmomanometer, mmHg.;Vitamin D serum level. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: ng/ml.	—

Measure

Time frame

Systolic blood pressure. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: Sphygmomanometer, mmHg.;Diastolic blood pressure. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: Sphygmomanometer, mmHg.;Mean arterial pressure. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: Sphygmomanometer, mmHg.;Vitamin D serum level. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: ng/ml.

—

Secondary

Measure	Time frame
Adverse effect of vitamin D supplement. Timepoint: 8 weeks after treatment. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Rostami-Yalmeh

Baqiyatallah University of Medical Sciences

javadrostami67@yahoo.com+98 21 8248 2516

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026